We live in a world where $1 billion of prescription medications are left at the pharmacy counter each year, often because ...

Eli Lilly and Novo Nordisk already produce popular GLP-1s in the Triangle. A Swiss drugmaker says its future Wake County site ...

As the patent for semaglutide nears its end, Novo Nordisk's dominance in the weight-loss market is being challenged. The ...

With millions of Americans prescribed GLP-1 drugs, researchers warn of catastrophic risks ignored by Big Pharma.

Representative Marjorie Taylor Greene is back in the spotlight for her stock trades, this time taking a stake in the ...

Prescription savings platform GoodRx is collaborating with pharma giant Novo Nordisk to make Ozempic and Wegovy pens ...

Jameela Jamil issued multiple clarifications after posting about Serena Williams' recent endorsement of weight loss ...

Dentists claim weight-loss drugs could majorly impact users' saliva glands, helping gum disease to fester in their mouths.

Hims & Hers investors hit with more bad news as Novo Nordisk partners with GoodRx to offer discounted access to competing products. ETFs with high concentration in HIMS may face risks and losses.

GreensKeeper Asset Management, an investment management company, released its second-quarter 2025 investor letter. A copy of ...

As appetite-suppressing drugs change the way people eat, businesses are adapting to GLP-1 users by offering smaller portions and protein-focused options ...